{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002841","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.322253+00:00","generated_at":"2026-05-22T07:35:27.345526+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus presents HBV functional cure data from imdusiran combo; AB-101 safety at EASL 2025","bullets":["In Phase 2a IM-PROVE II, imdusiran + VTP-300 + low-dose nivolumab led to 15.3% functional cure rate (2/13) in patients with baseline HBsAg <1000 IU/mL.","3 patients in nivolumab cohort achieved HBsAg loss and seroconversion at week 48.","AB-101 Phase 1a/1b Part 3: 10mg once daily for 28 days well tolerated with PD-L1 receptor occupancy similar to healthy volunteers; no liver dysfunction.","Across all imdusiran Phase 2a trials, 8 patients functionally cured, 7 with baseline HBsAg <1000 IU/mL."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002841","json":"https://secwatch.observer/filing/0001171843-25-002841.json","markdown":"https://secwatch.observer/filing/0001171843-25-002841.md","text":"https://secwatch.observer/filing/0001171843-25-002841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325002841/0001171843-25-002841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325002841/f8k_050725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:35:27.345526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}